Franca Carlos Antônio da Silva, Vieira Sérgio Lannes, Carvalho Antonio Carlos Pires, Bernabe Antonio Jose Serrano, Penna Antonio Belmiro Rodrigues Campbell
Master, MD, Radiation Oncology at Instituto Brasileiro de Oncologia (IBO), Radioterapia Botafogo, Universidade Federal do Rio de Janeiro (UFRJ) and Pontifícia Universidade Católica do Rio de Janeiro (PUC-Rio), Rio de Janeiro, RJ, Brazil.
Full Professor, MD, Radiation Oncology at Instituto Brasileiro de Oncologia (IBO), Radioterapia Botafogo and Pontifícia Universidade Católica do Rio de Janeiro (PUC-Rio), Rio de Janeiro, RJ, Brazil.
Radiol Bras. 2014 Mar-Apr;47(2):89-93. doi: 10.1590/S0100-39842014000200010.
To evaluate the relationship between two year PSA nadir (PSAn) after brachytherapy and biochemical recurrence rates in prostate cancer patients.
In the period from January 1998 to August 2007, 120 patients were treated with iodine-125 brachytherapy alone. The results analysis was based on the definition of biochemical recurrence according to the Phoenix Consensus.
Biochemical control was observed in 86 patients (71.7%), and biochemical recurrence, in 34 (28.3%). Mean PSAn was 0.53 ng/ml. The mean follow-up was 98 months. The patients were divided into two groups: group 1, with two year PSAn < 0.5 ng/ml after brachytherapy (74 patients; 61.7%), and group 2, with two year PSAn ≥ 0.5 ng/ml after brachytherapy (46 patients; 38.3%). Group 1 presented biochemical recurrence in 15 patients (20.3%), and group 2, in 19 patients (43.2%) (p < 0.02). The analysis of biochemical disease-free survival at seven years, stratified by the two groups, showed values of 80% and 64% (p < 0.02), respectively.
Levels of two year PSAn ≥ 0.5 ng/ml after brachytherapy are strongly correlated with a poor prognosis. This fact may help to identify patients at risk for disease recurrence.
评估前列腺癌患者近距离放射治疗后两年前列腺特异抗原最低点（PSAn）与生化复发率之间的关系。
1998年1月至2007年8月期间，120例患者仅接受了碘-125近距离放射治疗。结果分析基于Phoenix共识对生化复发的定义。
86例患者（71.7%）观察到生化控制，34例（28.3%）出现生化复发。平均PSAn为0.53 ng/ml。平均随访时间为98个月。患者分为两组：第1组，近距离放射治疗后两年PSAn<0.5 ng/ml（74例患者；61.7%），第2组，近距离放射治疗后两年PSAn≥0.5 ng/ml（46例患者；38.3%）。第1组有15例患者（20.3%）出现生化复发，第2组有19例患者（43.2%）出现生化复发（p<0.02）。按两组分层的七年无生化疾病生存率分析显示，分别为80%和64%（p<0.02）。
近距离放射治疗后两年PSAn≥0.5 ng/ml与预后不良密切相关。这一事实可能有助于识别疾病复发风险患者。
